Discovery of KRas G12C-IN-3 and Pomalidomide-based PROTACs as degraders of endogenous KRAS G12C with potent anticancer activity
Ling Li(Maryland Department of Health), Yinrong Wu(Southern Medical University), Chenglong Xu(Southern Medical University), Zichao Yang(Southern Medical University), Jingxuan Chen(East China University of Technology), Huiting Zhao(Jiangsu University), Jin Liu(Capital Medical University)
Cited by 40
Related Papers
Novel CRBN-Recruiting Proteolysis-Targeting Chimeras as Degraders of Stimulator of Interferon Genes with In Vivo Anti-Inflammatory Efficacy
|Journal of Medicinal Chemistry|2022|94
Mixed Lignan−Neolignans from <i>Tarenna attenuata</i>
|Journal of Natural Products|2007|74
Biosynthetic molecular imaging probe for tumor-targeted dual-modal fluorescence/magnetic resonance imaging
|Biomaterials|2020|39
<p>The Effect of Size, Dose, and Administration Route on Zein Nanoparticle Immunogenicity in BALB/c Mice</p>
|International Journal of Nanomedicine|2019|31
Discovery of Thieno[2,3-d]pyrimidine-based KRAS G12D inhibitors as potential anticancer agents via combinatorial virtual screening
|European Journal of Medicinal Chemistry|2022|29